CJ Bioscience announced on the 26th that it has submitted an IND of phase 1/2 of the Microbiome immuno-cancer drug "CJRB-101" to the U.S. Food and Drug Administration (FDA). CJRB-101 is a new immuno-cancer drug candidate secured by CJ Bioscience. It was developed through various immunological reviews based on the strain library that CJ has built. It is listed in the EFSA and has high safety for human administration, and unlike existing intestinal microorganisms, process development for mass production of medicines is underway, enabling long-term clinical trials for cancer patients. Phase 1/2 clinical trials evaluate the safety and preliminary efficacy of CJRB-101 in patients with metastatic cancer such as advanced or